TWI741286B - 治療癌症之方法 - Google Patents

治療癌症之方法 Download PDF

Info

Publication number
TWI741286B
TWI741286B TW108115047A TW108115047A TWI741286B TW I741286 B TWI741286 B TW I741286B TW 108115047 A TW108115047 A TW 108115047A TW 108115047 A TW108115047 A TW 108115047A TW I741286 B TWI741286 B TW I741286B
Authority
TW
Taiwan
Prior art keywords
weeks
bid
formula
mdm2 inhibitor
compound
Prior art date
Application number
TW108115047A
Other languages
English (en)
Chinese (zh)
Other versions
TW201945340A (zh
Inventor
偉恩 羅特柏姆
Original Assignee
美商卡托斯醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡托斯醫療公司 filed Critical 美商卡托斯醫療公司
Publication of TW201945340A publication Critical patent/TW201945340A/zh
Application granted granted Critical
Publication of TWI741286B publication Critical patent/TWI741286B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108115047A 2018-04-30 2019-04-30 治療癌症之方法 TWI741286B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862664673P 2018-04-30 2018-04-30
US62/664,673 2018-04-30
US201862701088P 2018-07-20 2018-07-20
US62/701,088 2018-07-20
US201862781942P 2018-12-19 2018-12-19
US62/781,942 2018-12-19
US201962834848P 2019-04-16 2019-04-16
US62/834,848 2019-04-16

Publications (2)

Publication Number Publication Date
TW201945340A TW201945340A (zh) 2019-12-01
TWI741286B true TWI741286B (zh) 2021-10-01

Family

ID=68386769

Family Applications (3)

Application Number Title Priority Date Filing Date
TW108115047A TWI741286B (zh) 2018-04-30 2019-04-30 治療癌症之方法
TW110132121A TW202146387A (zh) 2018-04-30 2019-04-30 治療癌症之方法
TW113138550A TW202529759A (zh) 2018-04-30 2019-04-30 治療癌症之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110132121A TW202146387A (zh) 2018-04-30 2019-04-30 治療癌症之方法
TW113138550A TW202529759A (zh) 2018-04-30 2019-04-30 治療癌症之方法

Country Status (20)

Country Link
US (2) US12115153B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787625A4 (cg-RX-API-DMAC10.html)
JP (2) JP2021523220A (cg-RX-API-DMAC10.html)
KR (2) KR20250130704A (cg-RX-API-DMAC10.html)
CN (2) CN120037232A (cg-RX-API-DMAC10.html)
AU (2) AU2019263064B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022148A2 (cg-RX-API-DMAC10.html)
CA (1) CA3098606A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020002833A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014599A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200576A (cg-RX-API-DMAC10.html)
IL (3) IL319432A (cg-RX-API-DMAC10.html)
JO (1) JOP20200273A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020011608A (cg-RX-API-DMAC10.html)
PE (1) PE20211653A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020551820A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202010793UA (cg-RX-API-DMAC10.html)
TN (1) TN2020000210A1 (cg-RX-API-DMAC10.html)
TW (3) TWI741286B (cg-RX-API-DMAC10.html)
WO (1) WO2019213074A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004225A2 (pt) * 2019-09-16 2022-05-31 Novartis Ag Uso de um inibidor de mdm2 para o tratamento de mielofibrose
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021175192A1 (en) * 2020-03-02 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
WO2022219128A1 (en) * 2021-04-15 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm
EP4398903A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION
EP4398905A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS OF TREATING CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140364455A1 (en) * 2013-06-10 2014-12-11 Amgen Inc. Processes of making and crystalline forms of a mdm2 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
PT3456333T (pt) * 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
WO2014134201A1 (en) * 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
KR102283895B1 (ko) * 2013-12-23 2021-07-30 노파르티스 아게 제약 조합물
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140364455A1 (en) * 2013-06-10 2014-12-11 Amgen Inc. Processes of making and crystalline forms of a mdm2 inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Leukemia & Lymphoma Society,"Myeloproliferative Neoplasms", 2019年12月17日取自網址:https://www.google.com/webhp?rlz=1C1GCEU_zh-TWTW821TW822&tbs=cdr:1#spf=1576568982475，2018年1月25日。

Also Published As

Publication number Publication date
IL278345B2 (en) 2024-05-01
JOP20200273A1 (ar) 2020-11-01
TW202146387A (zh) 2021-12-16
MX2024003655A (es) 2024-04-15
SG11202010793UA (en) 2020-11-27
WO2019213074A1 (en) 2019-11-07
US20250090517A1 (en) 2025-03-20
EP3787625A1 (en) 2021-03-10
CR20200576A (es) 2021-04-30
TW202529759A (zh) 2025-08-01
AU2019263064B2 (en) 2024-12-19
IL308399B2 (en) 2025-08-01
KR20210019422A (ko) 2021-02-22
CN120037232A (zh) 2025-05-27
IL278345A (cg-RX-API-DMAC10.html) 2020-12-31
PH12020551820A1 (en) 2021-07-26
MX2020011608A (es) 2021-02-17
IL308399B1 (en) 2025-04-01
TW201945340A (zh) 2019-12-01
KR102849513B1 (ko) 2025-08-25
BR112020022148A2 (pt) 2021-04-13
CN112512525A (zh) 2021-03-16
IL308399A (en) 2024-01-01
TN2020000210A1 (en) 2022-07-01
AU2025201686A1 (en) 2025-03-27
CL2020002833A1 (es) 2021-04-30
CA3098606A1 (en) 2019-11-07
EP3787625A4 (en) 2022-01-26
AU2019263064A1 (en) 2020-12-03
IL319432A (en) 2025-05-01
JP2021523220A (ja) 2021-09-02
IL278345B1 (en) 2024-01-01
US12115153B2 (en) 2024-10-15
CO2020014599A2 (es) 2021-02-26
KR20250130704A (ko) 2025-09-02
PE20211653A1 (es) 2021-08-24
US20210186946A1 (en) 2021-06-24
JP2024050668A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
US12371442B2 (en) Isoindolinone and indazole compounds for the degradation of EGFR
KR102849513B1 (ko) 암 치료 방법
US20260097028A1 (en) Methods of Treating Myeloproliferative Neoplasms
US20120316137A1 (en) Methods and Compositions for Treating Cancer
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
US20250199015A1 (en) Cyclin-dependent kinase 2 inhibitors for medical treatment
KR20240105382A (ko) 암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
US20240343728A1 (en) Compounds that inhibit pi3k isoform alpha and methods for treating cancer
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
KR20250151363A (ko) 골수증식성 신생물의 치료 방법
WO2023149450A1 (ja) Ｍａｌｔ１阻害薬を有効成分として含むがん治療剤
EA045240B1 (ru) Способы лечения рака
US20250387383A1 (en) Methods of treating myeloproliferative neoplasms
KR20250116120A (ko) 돌연변이 braf 분해제의 형태학적 형태 및 그의 제조 방법